Letter to the editorInfliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient
Section snippets
Case report
In 1998, polymyalgia rheumatica was diagnosed in a 55-year-old woman. Prednisolone was administered and progressively tapered until discontinuation in March 2003.
Three months later, inflammatory pain relapsed at the shoulders but also at the wrists, the metacarpo- and proximal interphalangeal joints (MCP and PIP) with synovitis as well as flexor and extensor tenosynovitis. ESR = 35 mm per first hour, CRP = 100 mg/l. Rheumatoid factors and anticitrullinated peptide antibodies were negative. Shoulder
Discussion
We describe the first case of infliximab induced skin and pulmonary sarcoidosis in a RA patient. Almost all case reports of anti-TNFα induced sarcoidosis are due to etanercept [5], [6] which is known to induce granulomatous diseases such as Crohn disease [7]. These discrepancies observed between monoclonal antibodies and soluble receptors are potentially linked to their differences in term of mechanism of action. In this regard, anti-TNFα monoclonal antibodies have been shown to induce more
References (10)
- et al.
Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts
Clin Dermatol
(2007) - et al.
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera
Rheumatology (Oxford)
(2002) - et al.
Sarcoidosis: an alveolar macrophage disease?
Sarcoidosis
(1989) - et al.
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
Am J Respir Crit Care Med
(2006) - et al.
Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients
Clin Rheumatol
(2007)